Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01242267 · OUTCOME

Complete Response (CR) and Very Good Partial Response (VgPR) Rate

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT · Source last updated 2026-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Assessments will be made from Day +28 after transplantation for 3 months and then at 3 month intervals until demonstration of disease progression and initiation of further therapy, an average of 9 months

What was measured

The complete response (CR) and very good partial response (VgPR) rate in patients undergoing ASCT using thalidomide, bortezomib and melphalan

Groups in this outcome

Phase I - Thalidomide Dose Level 600 mg

Phase I - Thalidomide Dose Level 600 mg

Phase I - Thalidomide Dose Level 800 mg

Phase I - Thalidomide Dose Level 800 mg

Phase I - Thalidomide Dose Level 1000 mg

Phase I - Thalidomide Dose Level 1000 mg

Phase 2

Phase 2 Thalidomide Dose Level 1000 mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I - Thalidomide Dose Level 600 mg3
Phase I - Thalidomide Dose Level 800 mg3
Phase I - Thalidomide Dose Level 1000 mg3
Phase 220

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase I - Thalidomide Dose Level 600 mg0Not reportedNot reportedNot reportedNot reported
Phase I - Thalidomide Dose Level 800 mg3Not reportedNot reportedNot reportedNot reported
Phase I - Thalidomide Dose Level 1000 mg1Not reportedNot reportedNot reportedNot reported
Phase 213Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        13
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      20
    units
    Participants
description
The complete response (CR) and very good partial response (VgPR) rate in patients undergoing ASCT using thalidomide, bortezomib and melphalan
groups
  1. description
    Phase I - Thalidomide Dose Level 600 mg
    id
    OG000
    title
    Phase I - Thalidomide Dose Level 600 mg
  2. description
    Phase I - Thalidomide Dose Level 800 mg
    id
    OG001
    title
    Phase I - Thalidomide Dose Level 800 mg
  3. description
    Phase I - Thalidomide Dose Level 1000 mg
    id
    OG002
    title
    Phase I - Thalidomide Dose Level 1000 mg
  4. description
    Phase 2 Thalidomide Dose Level 1000 mg
    id
    OG003
    title
    Phase 2
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Assessments will be made from Day +28 after transplantation for 3 months and then at 3 month intervals until demonstration of disease progression and initiation of further therapy, an average of 9 months
title
Complete Response (CR) and Very Good Partial Response (VgPR) Rate
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice